A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 276
- Registration Number
- NCT04288778
- Locations
- 🇮🇳
Jehangir Clinical Development Center Pvt Ltd, Pune, India
🇮🇳Chellaram Diabetes Institute, Pune, India
🇮🇳Nirmal Hospital Pvt. Ltd., Surat, India
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 150
- Registration Number
- NCT03768960
- Locations
- 🇮🇳
Post Graduate Institute of Medical Education And Research PGIMER, Chandigarh, India
🇮🇳Avron Hospitals Pvt. Ltd, Ahmedabad, India
🇮🇳M S Ramaiah Medical College and Hospital, Bengaluru, India
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 100
- Registration Number
- NCT03733925
- Locations
- 🇮🇳
ChanRe Rheumatology And Immunology Center And Research, Bangalore, India
🇮🇳Apollo Hospitals, Bhubaneswar, India
🇮🇳Chennai Meenakshi Multispeciality Hospital, Chennai, India
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 178
- Registration Number
- NCT03604224
- Locations
- 🇮🇳
Dr. A. Ramachandran's Diabetes Hospitals, Chennai, India
🇮🇳Apollo Hospitals, Kolkata, India
🇮🇳Diacon Hospital, Bangalore, India
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 40
- Registration Number
- NCT03476655
- Locations
- 🇮🇳
Apollo Hospitals International Limited, Ahmedabad, India
🇮🇳Healthcare Global (HCG) Hospital, Bangalore, India
🇮🇳Fortis Memorial Research Institute, Gurgaon, India
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 75
- Registration Number
- NCT03190330
- Locations
- 🇮🇳
Avron Hospitals Pvt. Ltd, Ahmedabad, India
🇮🇳Post Graduate Institute of Medical Education And Research PGIMER, Chandigarh, India
🇮🇳Basavatarakam Indo-American Hospital, Hyderabad, India
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Johnson & Johnson Private Limited
- Registration Number
- NCT02608359